Scientific publications

Download the publications

2022 “A Multicenter, Phase II, Open Label, Randomized Trial Evaluating Efficacy of Tedopi® Plus Docetaxel Or Tedopi Plus Nivolumab As Second-Line Therapy In Metastatic NSCLC Progressing After First-Line Chemo-Immunotherapy”, 2022 ASCO annual meeting
2022 “A randomized non-comparative phase II study of maintenance Tedopi® cancer vaccine alone or in combination with nivolumab, or FOLFIRI after induction with FOLFIRINOX in patients with advanced pancreatic ductal adenocarcinoma”, 2022 ASCO annual meeting
2022 “Quality of Life (QoL) of OSE2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO): Final data of Phase 3 Atalante-1 randomized trial”, 2022 ASCO annual meeting
2022 “Phase 2 clinical trial evaluating neo-epitope combination Tedopi® alone or in combination with Pembrolizumab versus best supportive care as maintenance treatment in platinum-sensitive recurrent ovarian cancer patients with disease control after platinum”, 2022 ASCO annual meeting
2022 Biomarker analyses from the Phase I clinical trial of the first-in-class SIRPα immune checkpoint inhibitor BI 765063 in patients with advanced solid tumors : AACR 2022 (American Association Cancer Research)
2021 Phase I dose escalation study in patients (pts) with advanced solid tumours receiving first-in-class BI 765063, a selective signal-regulatory protein α (SIRPα) inhibitor, in combination with ezabenlimab (BI 754091), a programmed cell death protein 1 (PD-1) inhibitor: ESMO (European Society for Medical Oncology) 2021
2021 Preclinical efficacy of CLEC-1 antagonist as novel myeloid immune checkpoint therapy for oncology: SITC (Society for Immunotherapy of Cancer) 2021
2021 Combined exploratory immunophenotyping and transcriptomic tumor analysis in patients treated with OSE2101 (Tedopi®) vaccine in HLA-A2+ advanced non-small cell lung cancer (NSCLC) from the ATALANTE-1 trial: SITC (Society for Immunotherapy of Cancer) 2021
2021 Long-term anti-tumor preclinical efficacy of an optimized anti-PD-1/IL-7 bifunctional antibody sustaining activation of progenitor stem-like CD8 TILs and disarming Treg suppressive activity: SITC (Society for Immunotherapy of Cancer) 2021
2021 Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO): Final results of Phase 3 Atalante-1 randomised trial: ESMO 2021
2021 Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up: ESMO 2016
2021 Safety, pharmacokinetics, efficacy, and preliminary biomarker data of first-in-class BI 765063, a selective SIRPα inhibitor: results of monotherapy dose escalation in Phase 1 study in patients with advanced solid tumors: ASCO 2021
2021 CLEC-1 is a novel myeloid immune checkpoint for cancer immunotherapy limiting tumor cells phagocytosis and tumor antigen cross-presentation: AACR 2021
2021 Triggering the resolution of inflammation with agonistic anti-ChemR23 antibody dampens inflammation-driven carcinogenesis and metastasis: AACR 2021
2021 BICKI®IL-7, optimized bifunctional anti PD-1/IL-7 drug, with good PK profile and preclinical anti-tumor efficacy: AACR 2021
2021 Agonist anti-ChemR23 mAb reduces tissue neutrophil accumulation and triggers chronic inflammation resolution: Science Advances
2020 Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance: Journal of Clinical Investigation
2020 Tissue-resident memory CD8 T-cell responses elicited by a single injection of a multi-target COVID-19 vaccine: BioRxiv
1 2 3 4

To receive OSE Immunotherapeutics’ latest news